Skip to main content

Advertisement

Table 2 Adverse events of patients in 12 mg/day group (the 2/1 schedule)

From: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Adverse events Grade 1/2 Grade 3
First 2 cycles All cycles First 2 cycles All cycles
No. of patients % No. of patients % No. of patients % No. of patients %
Occurred at least one time 21 100 21 100 2 10 6 29
Hand-foot skin reaction 4 19 10 48 0 0 1 5
Rash 4 19 6 29 0 0 0 0
Hypertension 5 24 5 24 0 0 2 10
Proteinuria 5 24 14 67 0 0 0 0
Triglyceride elevation 6 29 11 52 1 5 2 10
Total cholesterol elevation 6 29 13 62 0 0 0 0
Hypothyroidism 8 38 12 57 0 0 0 0
Hyperthyroidism 2 10 2 10 0 0 0 0
ALT elevation 6 29 10 48 0 0 0 0
AST elevation 4 19 9 43 0 0 0 0
Creatinine elevation 1 5 2 10 0 0 0 0
Total bilirubin elevation 5 24 8 38 0 0 0 0
Lipase elevation 1 5 5 24 1 5 1 5
Serum amylase 4 19 9 43 0 0 0 0
Myocardial enzymes abnormal 2 10 3 14 0 0 0 0
Leukopenia 3 14 6 29 0 0 0 0
Neutropenia 0 0 2 10 0 0 0 0
Thrombocytopenia 0 0 2 10 0 0 0 0
Hemorrhage 0 0 1 5 0 0 0 0
Urine occult blood 5 24 8 38 0 0 0 0
Fatigue 5 24 7 33 0 0 0 0
Diarrhea 6 29 7 33 0 0 0 0
Hoarseness 3 14 5 24 0 0 0 0
Nausea 3 14 3 14 0 0 0 0
Inappetence 1 5 2 10 0 0 0 0
Toothache 1 5 4 19 0 0 0 0
Pharyngalgia 1 5 4 19 0 0 0 0
Premature beat 0 0 1 5 0 0 0 0
  1. ALT alanine aminotransferase, AST aspartate transaminase